Camp4 Therapeutics Corporation (CAMP)

Camp4 Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-86.3	-80.4	-51.79	-49.29	-44.19
Depreciation & Amortization	1.74	1.64	1.7	1.68	0.88
Stock-Based Compensation	4.61	4	4.03	2.91	1.38
Other Adjustments	35.8	32.21	1.83	1.82	1.69
Changes in Accounts Payable	-0.61	-1.03	0.17	-1.12	1.33
Changes in Accrued Expenses	2.22	0.81	1.53	-0.14	1.89
Changes in Unearned Revenue	16.29	17.12	0.39	-	-
Changes in Other Operating Activities	-2.04	-3.88	-3.42	-0.02	-1.52
Operating Cash Flow	-26.25	-29.55	-45.56	-44.16	-38.54
Capital Expenditures	-	-0.28	-0.44	-0.68	-4.03
Sale of Property, Plant & Equipment	-	0.04	-	-	-
Investing Cash Flow	0.04	-0.24	-0.44	-0.68	-4.03
Long-Term Debt Issued	-	-	-	0.71	-
Long-Term Debt Repaid	0.02	-0.1	-0.46	-0.27	-
Net Long-Term Debt Issued (Repaid)	0.02	-0.1	-0.46	0.44	-
Issuance of Common Stock	32.61	61.17	76.47	0.19	0.06
Net Common Stock Issued (Repurchased)	32.61	61.17	76.47	0.19	0.06
Issuance of Preferred Stock	-	-	-	-	100.2
Net Preferred Stock Issued (Repurchased)	-	-	-	-	100.2
Other Financing Activities	-0.08	14.82	-4.34	-0.32	-0.09
Financing Cash Flow	76.1	75.89	71.66	0.3	100.16
Net Cash Flow	49.89	46.09	25.66	-44.53	57.59
Free Cash Flow	-26.25	-29.83	-46	-44.83	-42.57
FCF Margin	-667.21%	-852.83%	-7055.67%	-12809.40%	-
Free Cash Flow Per Share	-0.66	-0.98	-9.81	-113.51	-119.32
Levered Free Cash Flow	-68.68	-66.13	-52.33	-49.12	-45.64
Unlevered Free Cash Flow	-34.92	-38.19	-53.16	-52.15	-46.44

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q